FDA Approves Saphnelo Self-Administration for Lupus
Key Questions
What new FDA approval did Saphnelo receive for lupus treatment?
The FDA approved Saphnelo (anifrolumab) for self-administration via an autoinjector pen as a once-weekly subcutaneous option for systemic lupus erythematosus (SLE). This is supported by TULIP-SC and LTE data showing DORIS remission rates, plus Phase 2 lupus nephritis findings.
What real-world evidence supports anifrolumab use in lupus patients?
Spanish real-world data showed 93% CLASI-A50 responses at 6 months in refractory discoid lupus erythematosus with notable steroid-sparing effects. A separate 12-month study confirmed SLEDAI-2K improvements, steroid tapering, and LDN reduction alongside mechanistic insights.
How effective is Saphnelo for cutaneous lupus and long-term use?
Four-year data demonstrate sustained efficacy with biomarker improvements and BICLA response correlation. A systematic review confirms anifrolumab's efficacy in cutaneous lupus erythematosus alongside other targeted therapies.
AstraZeneca's Saphnelo (anifrolumab) gains FDA approval for self-administration via autoinjector pen for once-weekly subQ SLE (TULIP-SC/LTE DORIS remission data), plus real-world refractory DLE responses and Ph2 LN data. New real-world evidence from Spain shows 93% CLASI-A50 response at 6 months and significant steroid-sparing. Four-year data confirm sustained efficacy with biomarker improvements and BICLA response correlation. A new 12-month real-world study reinforces effectiveness with SLEDAI-2K improvement, steroid tapering, and LDN reduction, adding mechanistic insights. A systematic review confirms anifrolumab's efficacy in CLE alongside other targeted therapies.